Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 2 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Protein and Peptide-based Therapeutics - Introduction | 7 | 1 |
| Protein and Peptide-based Therapeutics - Market Overview | 8 | 11 |
| Introduction to the Physiological Relevance of Proteins and Peptides | 8 | 1 |
| The Organization and Structure of Proteins and Peptides | 8 | 1 |
| The Application of Protein and Peptide-based Molecules for Therapeutic Purposes | 9 | 9 |
| Benefits and Disadvantages of Protein and Peptide-based Therapeutics | 18 | 1 |
| Review of the Discovery and Development Process of Protein and Peptide-based Therapeutic Molecules | 19 | 7 |
| Overview of the Discovery Phase | 19 | 2 |
| Compound Screening Technology | 21 | 1 |
| Phage-display Peptide Library Screening | 21 | 1 |
| Drug Delivery, Bioavailability and Degradation | 21 | 1 |
| Primary Challenges for Drug Delivery, Bioavailability and Degradation | 21 | 1 |
| Strategies for Improved Bioavailability and Stability of Protein and Peptide-based Therapeutics | 22 | 1 |
| Modification of L-Amino Acids to D-isomers for Improved Protection from Enzymatic Degradation | 22 | 1 |
| Design of Cyclic Peptides | 22 | 1 |
| Carrier Systems | 23 | 1 |
| Delivery of Peptide and Protein Therapeutic Molecules as Prodrugs or Conjugates | 23 | 1 |
| Modifications of Protein and Peptide-based Therapeutics | 24 | 1 |
| Glycosylation, Phosphorylation and Proteolytic Cleavage | 24 | 1 |
| Rational Drug Design | 25 | 1 |
| Bioinformatic and Structural Computational Approach to Drug Design | 25 | 1 |
| Summary of the Manufacturing Processes of Protein and Peptide-based Therapeutics | 26 | 2 |
| Recombinant Cell Line Production of Protein and Peptide-based Therapeutics | 26 | 1 |
| Peptide Synthesis | 27 | 1 |
| Regulatory Environment for Protein and Peptide-based Therapeutics | 28 | 2 |
| Patent Protection | 28 | 1 |
| Exclusivity for Biological Products | 28 | 2 |
| Pipeline Analysis of Protein and Peptide-based Therapeutics | 30 | 6 |
| Overview of the Distribution of Protein and Peptide-based Therapeutics across Developmental Stages | 30 | 1 |
| Pipeline Molecules per Therapeutic Area | 31 | 1 |
| Overview of Targeted Cell Types, Functions and Mechanisms of Action of the Pipeline Molecules | 32 | 3 |
| Route of Administration of Pipeline Molecule Developments | 35 | 1 |
| Licensing Deals for Protein and Peptide-based Therapeutics | 36 | 6 |
| | 37 | 1 |
| Hanwha Chemical Enters into Licensing Agreement with Merck for HD203 | 37 | 1 |
| Sanofi Enters into Licensing Agreement with Oxford BioMedica for TroVax | 38 | 1 |
| Cephalon Enters into Licensing Agreement with ImmuPharma for Lupuzor | 38 | 1 |
| BioMS Medical Enters into Licensing Agreement with Eli Lilly for MBP8298 | 38 | 1 |
| Human Genome Sciences Enters into Licensing Agreement with FivePrime Therapeutics for FP-1039 | 38 | 1 |
| Novacea Enters into Licensing Agreement with Schering-Plough for Asentar | 39 | 1 |
| Celldex Therapeutics Enters into Licensing and Development Agreement with Pfizer | 39 | 1 |
| Allergan Enters into Licensing Agreement with Molecular Partners for MP0112 | 39 | 1 |
| Onyx Pharma Enters into Licensing Agreement with Ono Pharma for Carfilzomib and ONX 0912 | 40 | 1 |
| Forest Labs Enters into Licensing Agreement with Microbia | 40 | 1 |
| NPS Pharma Enters into Licensing Agreement with Nycomed for Gattex | 40 | 1 |
| Pfizer Enters into Licensing Agreement with Scil Technology | 40 | 1 |
| Cubist Pharma Enters into Licensing Agreement with Dyax | 41 | 1 |
| Merck Serono Enters into Licensing Agreement with Apitope Technology | 41 | 1 |
| Protein and Peptide-based Therapeutics Appendix | 42 | 3 |
| Abbreviations | 42 | 1 |
| Sources | 42 | 3 |
| Research Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Pipeline Analysis | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 44 | 1 |